Test Lists

  • Regression Package Testing List Page
Publisher QA3 - UPP Test
  • Regression Package Testing List Page
1 / 0

Recombinetics Inc. Announces Study to Improve Outcomes for Rare Disease Patients

November 2, 2020
By Recombinetics Inc.
Alt Text FF - Home Screen Icon 3
Caption FF
Description FF
Share this...
  • Facebook
  • Pinterest
  • Twitter
  • Linkedin

EAGAN, Minn., Nov. 2, 2020 /PRNewswire/ — Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and animal agriculture, today announced a first-of-its-kind study to improve outcomes for patients diagnosed with a rare disease known as Tuberous Sclerosis Complex (TSC).

Surrogen, a subsidiary of Recombinetics Inc., is focused on developing large animal models of human disease for use in medical research. This technology allows researchers to engineer exact patient mutations into the swine genome to develop biomedical models to study disease and find new therapies that are both safe and effective for patients.  

TSC is a rare disease that occurs in 1 in 6,000 births. There are over 1 million individuals with TSC worldwide. TSC causes tumors that form in vital organs including the brain, eyes, heart, liver, lungs, and skin. In addition, autism, seizures and serious neurodevelopmental delay can occur. There are currently no treatments that can eliminate tumor cells in TSC, and no animal models that fully recapitulate the disease, creating a research bottleneck. Recombinetics Inc. will work with Boston’s Brigham and Women’s Hospital to advance research by creating reproducible and reliable animal models for pre-clinical studies, leading to new treatments for TSC.

According to Dr. Adrienne Watson, Recombinetics Inc.  Vice President of Research and Development, “This new model of TSC will mirror the human disease genetically and is expected to show the same pathophysiology seen in human patients. This gives the research and therapeutics community an unprecedented opportunity to fully understand this disease and improve the lives of patients through the development of biomarkers, new surgical and imaging techniques, and new therapies to treat the many complications that patients with TSC face.” 

“We couldn’t be more excited to be working with Brigham and Women’s Hospital to bring hope and healing to those who suffer from this insidious disease,” said Mark Platt, Recombinetics Inc.’s President and Chief Executive Officer.  “The opportunity to study this disease, as well as many others, in large animal models with the exact human genetics is a game changer that will speed new therapeutic development at lower cost and lower patient risk.”

“Decades of experience has shown that mouse models of TSC fail to reproduce the fundamental pathology and tumor growth characteristics that occur in TSC.  Hence, we are very excited and hopeful that this new swine model of TSC will reproduce the classic TSC lesions, enabling detailed studies of how they develop as well as assessment of novel therapeutic approaches,” said David J. Kwiatkowski, MD, PhD, and Elizabeth P. Henske, MD, both of Brigham and Women’s Hospital and Professors of Medicine at Harvard Medical School.

This project is supported by a gift from Cristy and Jim Wade of Texas, whose family is personally affected by TSC. The Wades state, “We are excited to help with this new line of research and are very hopeful this model will ultimately result in treatments to help those individuals and their families living with TSC.”

About Recombinetics

Founded in 2008, Recombinetics is a recognized global leader in the development, deployment, and commercialization of genetically engineered animals.  Its four subsidiaries, Regenevida, Surrogen, Makana, and Acceligen, have delivered hundreds of animals to enable drug, device and therapeutic discovery, generate transplantable cells, tissues and organs, and provide improved health, well-being, and productivity of agricultural animals.

Website:  recombinetics.com

CONTACT:  Nikki Rockstroh, 257931@email4pr.com, 612-727-2000

Categories: Madison Magazine Logo

Latest Stories

Eu Regulator Authorizes Astrazeneca Vaccine For All Adults

EU regulator authorizes AstraZeneca vaccine for all adults

Rayos Syndication User,
KXLY-Latest Stories

Regulators authorized AstraZeneca’s coronavirus vaccine for use in adults throughout the European Union on Friday, amid criticism the bloc is not moving fast enough to vaccinate its population.

Ex Fbi Lawyer Given Probation For Russia Probe Actions

Ex-FBI lawyer given probation for Russia probe actions

Rayos Syndication User,
KXLY-Latest Stories

WASHINGTON (AP) — A former FBI lawyer was sentenced to probation for altering an email that the Justice Department relied on during its surveillance of an aide to President Donald Trump during the Russia investigation.

Evers: Repealing Mask Mandate Like Eliminating Speed Limits

Evers: Repealing mask mandate like eliminating speed limits

Rayos Syndication User,
KXLY-Latest Stories

MADISON, Wis. (AP) — Democratic Gov. Tony Evers lashed out Friday at rival Republicans who tried to repeal his statewide mask mandate, saying killing the order would be a ridiculous move comparable to abolishing speed limits.

Conservatives Praise South Carolina Win On Abortion Ban

Conservatives praise South Carolina win on abortion ban

Rayos Syndication User,
KXLY-Latest Stories

COLUMBIA, S.C. (AP) — As some conservatives in South Carolina celebrated getting a bill that would ban almost all abortions in the state past a legislative barrier and likely becoming law, they said they are not finished trying to end all abortions.

Moscow Court Puts Navalny’s Allies Under House Arrest

Moscow court puts Navalny's allies under house arrest

Rayos Syndication User,
KXLY-Latest Stories

A Moscow court on Friday put the brother and several allies of Russian opposition leader Alexei Navalny under house arrest for two months as authorities sought to stymie more protests over the jailing of the top Kremlin foe.

Most Popular

9:40 Future Import Test

One more current test NW

Current UPP Import NW

Test New Article 12092025 - 4 - Message

Test New Article 12092025 - 4 - Election

Test New Article 12092025 - 2 - Closing

© 2026 Publisher QA3 – UPP Test.

Privacy Policy
Powered byBLOX Digital
X